Craneware Valuation

Q: What is the Fair Price of CRW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CRW (£22.8) is trading above our estimate of [[fair value]] (£18.31)

Is CRW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRW (£22.8) is trading above our estimate of fair value (£18.31)

Significantly Below Fair Value: CRW is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRW?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CRW. This is calculated by dividing CRW's market cap by their current preferred multiple.
What is CRW's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$1.05b

CRW key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.6x
Enterprise Value/EBITDA	30.7x
PEG Ratio	3.5x

Price to Earnings Ratio vs Peers

How does CRW's PE Ratio compare to its peers?

The above table shows the PE ratio for CRW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	38.8x
EMIS EMIS Group	40.4x	11.0%	UK£1.2b
INS Instem	59.8x	n/a	UK£199.6m
CVSG CVS Group	22.7x	12.1%	UK£802.0m
AMS Advanced Medical Solutions Group	32.2x	15.5%	UK£511.5m
CRW Craneware	89.7x	25.6%	UK£796.9m

Price-To-Earnings vs Peers: CRW is expensive based on its Price-To-Earnings Ratio (89.7x) compared to the peer average (27.4x).

Price to Earnings Ratio vs Industry

How does CRW's PE Ratio compare vs other companies in the European Healthcare Services Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.1%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: CRW is expensive based on its Price-To-Earnings Ratio (89.7x) compared to the European Healthcare Services industry average (17.6x).

Price to Earnings Ratio vs Fair Ratio

What is CRW's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRW PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	89.7x
Fair PE Ratio	32.8x

Price-To-Earnings vs Fair Ratio: CRW is expensive based on its Price-To-Earnings Ratio (89.7x) compared to the estimated Fair Price-To-Earnings Ratio (32.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRW forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	UK£22.80	UK£28.74 +26.1%	4.9%	UK£30.68	UK£26.98	n/a	5
Aug ’25	UK£23.00	UK£27.32 +18.8%	4.0%	UK£29.22	UK£25.87	n/a	5
Jul ’25	UK£23.10	UK£26.87 +16.3%	4.5%	UK£29.05	UK£25.41	n/a	5
Jun ’25	UK£24.60	UK£26.75 +8.8%	4.6%	UK£28.92	UK£25.29	n/a	5
May ’25	UK£22.40	UK£27.11 +21.0%	4.9%	UK£29.40	UK£25.71	n/a	5
Apr ’25	UK£22.00	UK£26.85 +22.1%	4.7%	UK£29.07	UK£25.42	n/a	5
Mar ’25	UK£21.10	UK£26.25 +24.4%	8.1%	UK£28.68	UK£22.83	n/a	4
Feb ’25	UK£21.10	UK£24.50 +16.1%	13.5%	UK£28.64	UK£19.99	n/a	4
Jan ’25	UK£17.50	UK£24.01 +37.2%	14.4%	UK£28.00	UK£18.88	n/a	4
Dec ’24	UK£16.50	UK£23.63 +43.2%	17.4%	UK£28.08	UK£17.23	n/a	4
Nov ’24	UK£16.20	UK£24.51 +51.3%	18.2%	UK£29.69	UK£18.00	n/a	4
Oct ’24	UK£15.00	UK£24.39 +62.6%	18.1%	UK£29.47	UK£17.87	n/a	4
Sep ’24	UK£13.75	UK£26.81 +95.0%	9.0%	UK£29.53	UK£23.65	UK£21.50	3
Aug ’24	UK£13.30	UK£25.37 +90.8%	9.4%	UK£28.72	UK£23.01	UK£23.00	4
Jul ’24	UK£13.65	UK£25.23 +84.8%	7.0%	UK£27.80	UK£22.98	UK£23.10	4
Jun ’24	UK£14.30	UK£25.81 +80.5%	8.0%	UK£28.64	UK£22.94	UK£24.60	4
May ’24	UK£13.50	UK£25.81 +91.2%	8.0%	UK£28.64	UK£22.94	UK£22.40	4
Apr ’24	UK£11.50	UK£25.81 +124.4%	8.0%	UK£28.64	UK£22.94	UK£22.00	4
Mar ’24	UK£14.40	UK£26.26 +82.4%	11.6%	UK£31.09	UK£22.95	UK£21.10	4
Feb ’24	UK£14.30	UK£26.26 +83.6%	11.6%	UK£31.09	UK£22.95	UK£21.10	4
Jan ’24	UK£18.15	UK£28.08 +54.7%	10.4%	UK£31.20	UK£24.18	UK£17.50	3
Dec ’23	UK£21.95	UK£28.08 +27.9%	10.4%	UK£31.20	UK£24.18	UK£16.50	3
Nov ’23	UK£18.65	UK£28.39 +52.3%	9.6%	UK£31.09	UK£24.67	UK£16.20	3
Oct ’23	UK£19.30	UK£29.10 +50.8%	7.6%	UK£31.20	UK£26.04	UK£15.00	3
Sep ’23	UK£15.90	UK£28.92 +81.9%	14.2%	UK£32.42	UK£23.14	UK£13.75	3

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.